Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| lung | 16 studies | 35% ± 15% | |
| peripheral blood | 15 studies | 32% ± 12% | |
| intestine | 11 studies | 35% ± 17% | |
| kidney | 8 studies | 37% ± 11% | |
| liver | 8 studies | 36% ± 22% | |
| eye | 5 studies | 30% ± 9% | |
| lymph node | 5 studies | 38% ± 12% | |
| uterus | 4 studies | 43% ± 17% | |
| prostate | 4 studies | 26% ± 9% | |
| breast | 4 studies | 29% ± 7% | |
| brain | 4 studies | 21% ± 3% | |
| pancreas | 3 studies | 45% ± 17% | |
| placenta | 3 studies | 35% ± 10% | |
| bone marrow | 3 studies | 23% ± 5% | |
| adrenal gland | 3 studies | 26% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| adrenal gland | 100% | 1032.51 | 258 / 258 | 0% | 0 | 0 / 230 |
| bladder | 100% | 750.67 | 21 / 21 | 0% | 0 | 0 / 504 |
| breast | 100% | 901.75 | 459 / 459 | 0% | 0 | 0 / 1118 |
| esophagus | 100% | 845.03 | 1445 / 1445 | 0% | 0 | 0 / 183 |
| intestine | 100% | 964.69 | 966 / 966 | 0% | 0 | 0 / 527 |
| kidney | 100% | 1618.82 | 89 / 89 | 0% | 0 | 0 / 901 |
| liver | 100% | 3759.46 | 226 / 226 | 0% | 0 | 0 / 406 |
| ovary | 100% | 691.76 | 180 / 180 | 0% | 0 | 0 / 430 |
| pancreas | 100% | 1258.59 | 328 / 328 | 0% | 0 | 0 / 178 |
| prostate | 100% | 1000.36 | 245 / 245 | 0% | 0 | 0 / 502 |
| spleen | 100% | 582.29 | 241 / 241 | 0% | 0 | 0 / 0 |
| stomach | 100% | 1130.20 | 359 / 359 | 0% | 0 | 0 / 286 |
| uterus | 100% | 564.24 | 170 / 170 | 0% | 0 | 0 / 459 |
| skin | 100% | 794.28 | 1808 / 1809 | 0% | 0 | 0 / 472 |
| adipose | 100% | 940.15 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| thymus | 100% | 766.59 | 652 / 653 | 0% | 0 | 0 / 605 |
| blood vessel | 100% | 718.51 | 1331 / 1335 | 0% | 0 | 0 / 0 |
| brain | 100% | 607.45 | 2629 / 2642 | 0% | 0 | 0 / 705 |
| muscle | 100% | 624.65 | 799 / 803 | 0% | 0 | 0 / 0 |
| lung | 99% | 644.28 | 575 / 578 | 0% | 0 | 0 / 1155 |
| peripheral blood | 97% | 731.85 | 901 / 929 | 0% | 0 | 0 / 0 |
| heart | 97% | 874.36 | 835 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0050729 | Biological process | positive regulation of inflammatory response |
| GO_0042438 | Biological process | melanin biosynthetic process |
| GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
| GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
| GO_0010760 | Biological process | negative regulation of macrophage chemotaxis |
| GO_0005615 | Cellular component | extracellular space |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0050178 | Molecular function | phenylpyruvate tautomerase activity |
| GO_0004167 | Molecular function | dopachrome isomerase activity |
| GO_0033981 | Molecular function | D-dopachrome decarboxylase activity |
| GO_0005126 | Molecular function | cytokine receptor binding |
| Gene name | DDT |
| Protein name | D-dopachrome tautomerase (D-dopachrome tautomerase, isoform CRA_b) (cDNA FLJ76419, highly similar to Homo sapiens D-dopachrome tautomerase (DDT), mRNA) D-dopachrome decarboxylase (EC 4.1.1.84) (D-dopachrome tautomerase) (Phenylpyruvate tautomerase II) D-dopachrome decarboxylase (D-dopachrome tautomerase) D-dopachrome decarboxylase (EC 4.1.1.84) |
| Synonyms | hCG_41098 DDT1 |
| Description | FUNCTION: Tautomerization of D-dopachrome with decarboxylation to give 5,6-dihydroxyindole (DHI). . FUNCTION: Tautomerization of D-dopachrome with decarboxylation to give 5,6-dihydroxyindole (DHI). . |
| Accessions | ENST00000350608.7 [P30046-1] ENST00000703965.1 Q53Y51 ENST00000403754.7 ENST00000629401.2 [P30046-2] H7C342 J3KQ18 ENST00000629936.1 P30046 ENST00000626871.2 [P30046-1] ENST00000428792.1 ENST00000430101.2 [P30046-2] B5MC82 ENST00000626046.2 ENST00000398344.9 [P30046-1] ENST00000626838.1 ENST00000615721.3 [P30046-1] |